$Hims & Hers Health Inc.(HIMS)

$Hims & Hers Health Inc.(HIMS)$ After a 100% run, HIMS might be priced for perfection. Here's why I’d be cautious here:

💸 Valuation Risk: At these levels, even small execution misses could trigger big sell-offs.
🏥 Competition Rising: Telehealth space is crowded—big players like Amazon and CVS are circling.
🔍 Still Unproven in Some Verticals: Their push into GLP-1 weight-loss drugs and mental health is early-stage and high-risk.

Momentum traders may stay in, but long-term investors should wait for a better entry. Chasing at the top rarely ends well.

HIMS Soars 16%! Will It Hit a New High in May?

Hims & Hers Health, Inc. (HIMS) surged nearly 16% on Tuesday. The momentum came after the telehealth company disclosed it had raised $1 billion last week, in its largest funding round to date. The stock is up 164% YTD! It closed at $64, only one step away from its all time high of 72.98. Can it aim higher and hit a new high in May?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":432838190620808,"tweetId":"432838190620808","gmtCreate":1746678306195,"gmtModify":1746681003295,"author":{"id":10000000000011856,"idStr":"10000000000011856","authorId":10000000000011856,"authorIdStr":"10000000000011856","name":"JimmyHua","avatar":"https://community-static.tradeup.com/news/7f17d426377c791ac5cdfef91fbf8408","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":495,"starInvestorFlag":false},"themes":[{"themeId":"5e806b9ca9c044dcb745dc2aa01d0767","categoryId":"7a15628ce2174325bddc6229505e0d70","name":"HIMS Soars 16%! Will It Hit a New High in May?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":5e806b9ca9c044dcb745dc2aa01d0767}&rnconfig={\"headerBarHidden\": true}","description":"Hims & Hers Health, Inc. (HIMS) surged nearly 16% on Tuesday. The momentum came after the telehealth company disclosed it had raised $1 billion last week, in its largest funding round to date.\nThe stock is up 164% YTD! \nIt closed at $64, only one step away from its all time high of 72.98.\nCan it aim higher and hit a new high in May?","image":"https://community-static.tradeup.com/news/bfb30c778747f6295146d2f087be6585"}],"images":[],"coverImages":[],"html":"<html><head></head><body> <a data-mention-id=\"HIMS\" class=\"teditor-mention\" data-mention-name=\"Hims &amp; Hers Health Inc.\" href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$</a> After a 100% run, HIMS might be priced for perfection. Here's why I’d be cautious here:<ul style=\"\"><li>💸 Valuation Risk: At these levels, even small execution misses could trigger big sell-offs.</li><li>🏥 Competition Rising: Telehealth space is crowded—big players like Amazon and CVS are circling.</li><li>🔍 Still Unproven in Some Verticals: Their push into GLP-1 weight-loss drugs and mental health is early-stage and high-risk.</li></ul>Momentum traders may stay in, but long-term investors should wait for a better entry. Chasing at the top rarely ends well.</body></html>","htmlText":"<html><head></head><body> <a data-mention-id=\"HIMS\" class=\"teditor-mention\" data-mention-name=\"Hims &amp; Hers Health Inc.\" href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$</a> After a 100% run, HIMS might be priced for perfection. Here's why I’d be cautious here:<ul style=\"\"><li>💸 Valuation Risk: At these levels, even small execution misses could trigger big sell-offs.</li><li>🏥 Competition Rising: Telehealth space is crowded—big players like Amazon and CVS are circling.</li><li>🔍 Still Unproven in Some Verticals: Their push into GLP-1 weight-loss drugs and mental health is early-stage and high-risk.</li></ul>Momentum traders may stay in, but long-term investors should wait for a better entry. Chasing at the top rarely ends well.</body></html>","text":"$Hims & Hers Health Inc.(HIMS)$ After a 100% run, HIMS might be priced for perfection. Here's why I’d be cautious here: 💸 Valuation Risk: At these levels, even small execution misses could trigger big sell-offs. 🏥 Competition Rising: Telehealth space is crowded—big players like Amazon and CVS are circling. 🔍 Still Unproven in Some Verticals: Their push into GLP-1 weight-loss drugs and mental health is early-stage and high-risk. Momentum traders may stay in, but long-term investors should wait for a better entry. Chasing at the top rarely ends well.","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/432838190620808","repostId":0,"isVote":1,"tweetType":1,"viewCount":894,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["HIMS"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":469,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/432838190620808"}